Moreover, the 36-month beta value for DNLI is 1.39. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for DNLI is 112.30M and currently, short sellers hold a 8.38% of that float. On April 23, 2024, DNLI’s average trading volume was 1.19M shares.
DNLI) stock’s latest price update
The stock price of Denali Therapeutics Inc (NASDAQ: DNLI) has dropped by -0.06 compared to previous close of 16.00. Despite this, the company has seen a fall of -10.37% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-09 that Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
DNLI’s Market Performance
Denali Therapeutics Inc (DNLI) has seen a -10.37% fall in stock performance for the week, with a -23.86% decline in the past month and a -7.68% plunge in the past quarter. The volatility ratio for the week is 4.08%, and the volatility levels for the past 30 days are at 4.31% for DNLI. The simple moving average for the last 20 days is -15.24% for DNLI’s stock, with a simple moving average of -24.02% for the last 200 days.
Analysts’ Opinion of DNLI
Many brokerage firms have already submitted their reports for DNLI stocks, with Citigroup repeating the rating for DNLI by listing it as a “Buy.” The predicted price for DNLI in the upcoming period, according to Citigroup is $32 based on the research report published on December 13, 2023 of the previous year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see DNLI reach a price target of $28. The rating they have provided for DNLI stocks is “Overweight” according to the report published on November 20th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to DNLI, setting the target price at $35 in the report published on October 24th of the previous year.
DNLI Trading at -16.60% from the 50-Day Moving Average
After a stumble in the market that brought DNLI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.00% of loss for the given period.
Volatility was left at 4.31%, however, over the last 30 days, the volatility rate increased by 4.08%, as shares sank -18.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.03% lower at present.
During the last 5 trading sessions, DNLI fell by -10.37%, which changed the moving average for the period of 200-days by -45.01% in comparison to the 20-day moving average, which settled at $18.68. In addition, Denali Therapeutics Inc saw -25.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNLI starting from SATO VICKI L, who sale 1,666 shares at the price of $18.29 back on Apr 15 ’24. After this action, SATO VICKI L now owns 118,043 shares of Denali Therapeutics Inc, valued at $30,471 using the latest closing price.
Krognes Steve E., the Director of Denali Therapeutics Inc, sale 92,500 shares at $20.50 during a trade that took place back on Apr 01 ’24, which means that Krognes Steve E. is holding 47,341 shares at $1,896,250 based on the most recent closing price.
Stock Fundamentals for DNLI
Current profitability levels for the company are sitting at:
- -0.6 for the present operating margin
- 0.95 for the gross margin
The net margin for Denali Therapeutics Inc stands at -0.44. The total capital return value is set at -0.18. Equity return is now at value -14.01, with -11.11 for asset returns.
Based on Denali Therapeutics Inc (DNLI), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.85. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 9.33.
Currently, EBITDA for the company is -179.97 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 6.51. The receivables turnover for the company is 122.42for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.65.
Conclusion
To wrap up, the performance of Denali Therapeutics Inc (DNLI) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
